Sale of treasury shares

Louvain-la-Neuve (Belgium), 27 February 2020 – 7am (CET) : IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that in accordance with Article 8:6 of the Royal Decree implementing the Code of Companies and Associations, IBA Investments SC, one of its subsidiaries, has sold IBA shares at the price set by law to Belgian Leverage SA, a subsidiary of Belgian Anchorage SC, as follows:

Following the transaction, IBA Investments SC holds 410,852 shares in IBA SA, representing 1.36% of the total number of shares issued by IBA.

To the knowledge of IBA, Belgian Anchorage SC and its subsidiary Belgian Leverage SA together hold a total of 6’404’668 shares in IBA, representing 21.25% of the total number of shares issued by IBA.

This press release is available on IBA SA’s website via the following link https://iba-worldwide.com/media-room.

Investor Relations
Soumya Chandramouli
Chief Financial Officer
investorrelations@iba-group.com
+32 10 47 58 90

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com